NEVO™: a new generation of sirolimus-eluting coronary stent

Abstract

EuroIntervention Supplement (2009) Vol. 5 (Supplement F) F88-F93 Introduction Drug eluting stents (DES) have dramatically improved the effectiveness of coronary stenting since the introduction of Cypher® in 2002. Cypher® demonstrated that controlled stent-based delivery of sirolimus, a potent cell-cycle inhibitor and anti-inflammatory agent, could significantly reduce late lumen loss and restenosis rates when compared to bare metal stents1. These benefits were observed for multiple patient and lesion categories and have been sustained for more than five years2. Taxus® (Boston Scientific, Natick, MA, USA), Endeavor® (Medtronic, Minneapolis, MN, USA) and Xience® (Abbott Laboratories. Abbott Park, Il, USA) followed the introduction of Cypher® (Cordis Corporation, Bridgewater, NJ, USA) and have also shown significant reductions in restenosis in controlled clinical trials3-5. These FDA-approved DES share several common design features: (a) a metallic scaffold, (b) a durable, strut-adherent polymer coating, and (c) an elutible antiproliferative agent to reduce neointimal hyperplasia. The latest advance in DES technology and successor to Cypher® is the NEVOTM sirolimus-eluting coronary stent. The primary changes made transitioning from Cypher® to NEVOTM are shown in Table 1. NEVOTM is produced from L605 cobalt chromium alloy and has a thin-strut (<100 μm), open-cell configuration for improved vessel conformability and deliverability. NEVOTM was completely redesigned from the original Conor CoStar® stent and will be NEVOTM: a new generation of sirolimus-eluting coronary stent